|
EconStor >
United Nations University (UNU) >
World Institute for Development Economics Research (UNU-WIDER), United Nations University >
WIDER Research Papers, United Nations University (UNU) >
Please use this identifier to cite or link to this item:
http://hdl.handle.net/10419/45100
|
| | |
Full metadata record
| DC Field | | Value | | Language |
| dc.contributor.author | | Li, Xuan | | en_US |
| dc.date.accessioned | | 2010-02-15 | | en_US |
| dc.date.accessioned | | 2011-04-26T07:40:50Z | | - |
| dc.date.available | | 2011-04-26T07:40:50Z | | - |
| dc.date.issued | | 2008 | | en_US |
| dc.identifier.isbn | | 978-92-9230-082-1 | | en_US |
| dc.identifier.uri | | http://hdl.handle.net/10419/45100 | | - |
| dc.description.abstract | | A comparative study is undertaken that explores Chinese and Indian pharmaceutical industries under different patent regimes. It is found that relative to India, which had implemented process patent until 2005, China with a product patent regime since 1993 suffers from both lower drug accessibility and availability (the latter is a missing parameter in the literature). Also, China lags behind in both lower R&D investment and patents filed by Chinese nationals. Based on these findings and associated legal interpretation, we conclude that higher patent protection in China generates negative impacts on the pharmaceutical industries. Thus, governments should utilize TRIPS flexibilities and other regimes like price control to offset the anticompetitive effect in designing patent policies. | | en_US |
| dc.language.iso | | eng | | en_US |
| dc.publisher | | UNU-WIDER Helsinki | | en_US |
| dc.relation.ispartofseries | | Research paper / UNU-WIDER 2008.36 | | en_US |
| dc.subject.jel | | O34 | | en_US |
| dc.subject.jel | | L65 | | en_US |
| dc.subject.jel | | F14 | | en_US |
| dc.subject.ddc | | 330 | | en_US |
| dc.subject.keyword | | product patent | | en_US |
| dc.subject.keyword | | process patent | | en_US |
| dc.subject.keyword | | TRIPS | | en_US |
| dc.subject.keyword | | pharmaceutical industries | | en_US |
| dc.subject.keyword | | China | | en_US |
| dc.subject.keyword | | India | | en_US |
| dc.subject.stw | | TRIPS | | en_US |
| dc.subject.stw | | Patentrecht | | en_US |
| dc.subject.stw | | Wohlfahrtseffekt | | en_US |
| dc.subject.stw | | Pharmazeutische Industrie | | en_US |
| dc.subject.stw | | China | | en_US |
| dc.subject.stw | | Indien | | en_US |
| dc.title | | The impact of higher standards in patent protection for pharmaceutical industries under the TRIPS Agreement: A comparative study of China and India | | en_US |
| dc.type | | Working Paper | | en_US |
| dc.identifier.ppn | | 571446388 | | en_US |
| dc.rights | | http://www.econstor.eu/dspace/Nutzungsbedingungen | | en_US |
| Appears in Collections: | | WIDER Research Papers, United Nations University (UNU)
|
Items in EconStor are protected by copyright, with all rights reserved, unless otherwise indicated.
|